Special Populations (SPO) Community

The Special Populations Community focuses on research with groups of patients that differ with regard to human development (pediatrics, geriatrics, pregnancy), gender, ethnicity, socioeconomic status, body condition (obesity/malnutrition), or lifestyle (drug dependence, smoking).

Community Mission

The mission of the Special Populations Community is to engage members in clinical pharmacology and translational medicine research across academia, regulatory agencies, and industry to understand factors that contribute to variable therapeutic outcomes in special populations.

Community Goals

  • Provide a Community environment that fosters the development of much needed scientific expertise in special populations, including an appreciation for the diversity of the research in special populations.
  • Encourage the development of innovative pharmacological tools to engage special populations in research.
  • Stimulate scientific collaborations among clinical pharmacologists with interests in special populations and encourage the sharing of knowledge about common challenges in conducting research in special populations.
  • Provide a platform to collaborate with regulatory agencies to disseminate knowledge and expertise for the enhancement of guidelines on special populations.
  • Support members to propose and sponsor programming for ASCPT Annual Meetings as well as webinars and other educational resources throughout the year that are of interest to the SPO Community.
  • Encourage feedback from the SPO Community members and be responsive to ideas, initiatives, and involvement.

Like on Facebook Join the LinkedIn Group

Upcoming Webinar
ASCPT Members-Only Webinar Presented by the Special Populations (SPO) Community
Title:  Ethnic Diversity and Drug Response: Drug Development Consequences
Date and Time: Thursday, January 21, 2021, 3:30 pm ET
Speaker: Annette Gross, PhD
Moderators: Elimika Pfuma Fletcher, PharmD, PhD, and Pooja Manchandani, PhD
Description: This presentation will provide an overview of inter-ethnic differences in drug response, inclusive of the intrinsic and extrinsic factors which can be associated with population differences in pharmacokinetics, pharmacodynamics, efficacy, and safety. Drug development considerations will be discussed in relation to potential inter-ethnic differences in drug response including relevant regulatory guidelines (e.g., ICH E5, ICH E17) and assessment of ethnic sensitivity, US Food & Drug Administration Clinical Trial Diversity initiative, requirements for clinical trial data in specific countries / ethnic groups, and implications for drug development strategies and design of clinical studies (e.g., Multiregional Clinical Trials, Bridging Studies).
Registration Link: 

Past Webinars


Violette Gijsen, MD, PhD

Community Chair

Pooja Manchandani, PhD

Community Vice Chair

M Chetty

Manoranjenni Chetty, PhD

Community Vice Chair

Bianca van Groen PharmD

Community Past Chair

SPO Steering Committee
Akshanth Polepally, PhD
Erica Woodahl, PhD
Malaz AbuTarif, PhD
Elimika Fletcher, PharmD, PhD
Kit Wun Kathy Cheung, PharmD
Manoranjenni Chetty, PhD
David Hahn, PhD
Stephani Stancil, PhD
Anh Duong, PharmD
Benjamin Weber, PharmD, PhD
Farzaneh Salem, PharmD, PhD
Martina Sahre, PhD
Youssef Roman, PharmD, PhD
* Webinar Sub-Committee members
* Communication Sub-Committee members

Photo Gallery
Recent News
  • ASCPT Members-Only Webinar Presented by the Pharmacometrics & Pharmacokinetics (PMK) and Regulatory Science (RS) Communities
    January 20, 2021
  • 2020 in the Year-View Mirror: Full Speed Ahead to 2021
    January 18, 2021
  • FDA News: Issue 2, January 2021
    January 13, 2021
Contact Us